Bridge Neurotech and Butterfly Network Team Up on Non-Invasive BCI

Bridge Neurotech has announced a partnership with Butterfly Network to develop a non-invasive brain-computer interface, pairing Butterfly's handheld ultrasound platform with Bridge Neurotech's neural interface program.

The collaboration, reported by Digital Health News, targets a device class that neither scalp EEG nor implanted electrode arrays currently serve well: a system that reads neural activity through the intact skull without surgery, at a form factor clinicians could realistically deploy outside the operating room.

What do we know about the deal?

The announcement names two partners with complementary assets:

• Butterfly Network — developer of a handheld, pocket-sized ultrasound device cleared for point-of-care imaging, with a single-sensor silicon chip at its core.
• Bridge Neurotech — a neurotechnology firm focused on non-invasive neural interfaces.

The companies will combine these capabilities to build a non-invasive brain-computer interface. The announcement did not specify a target patient population, an expected timeline for first-in-human testing, or a regulatory pathway.

Where does this fit in the BCI landscape?

Most implanted BCIs that have reached human trials — from arrays placed on or in cortex — require craniotomy and carry the infection and hardware-failure risks of any chronically implanted device. Surface modalities avoid surgery but have well-known limits: scalp EEG resolves cortical sources poorly and attenuates high-frequency activity; magnetoencephalography offers better spatial resolution but demands shielded rooms and cryogenic or similarly costly hardware.

Ultrasound sits between these poles. Focused ultrasound can detect blood-flow and mechanical changes tied to neural activity through the skull, and researchers have used the technique in animal work to decode motor and sensory information with spatial resolution beyond what scalp electrophysiology achieves. Whether that translates into a practical wearable interface for human patients remains unproven, and this partnership is at the announcement stage rather than the clinical-trial stage.

How should clinical neurophysiologists read this?

The deal signals commercial interest in modalities that would compete with, or complement, conventional EEG in long-term monitoring. If a non-invasive ultrasound-based interface reaches validated human use, it could change how reading rooms handle applications where electrophysiology's spatial resolution falls short — seizure localization support, motor decoding for assistive devices, or continuous bedside monitoring.

For now, nothing in the announcement affects current practice. No device from this partnership exists in the clinic, none has FDA clearance, and no human efficacy data accompany the deal.

What happens next?

Expect the field to watch for three milestones: a disclosed technical specification for the combined device, animal validation data, and any investigational device exemption filing that would open the door to human studies. Until those appear, this is a corporate partnership — a credible one, given Butterfly's installed ultrasound platform — but not yet clinical evidence.